Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Carcinoma, Transitional Cell"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 7106

Starter badań:

Tytuł:
Tumor stemness score to estimate epithelial-to-mesenchymal transition (EMT) and cancer stem cells (CSCs) characterization and to predict the prognosis and immunotherapy response in bladder urothelial carcinoma.
Autorzy:
Zhang Y; Department of Urology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Zhang X; Department of Urology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.; Institute of Urology, Capital Medical University, Beijing, China.
Huang X; Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Tang X; Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Zhang M; Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Li Z; Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Hu X; Department of Urology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.; Institute of Urology, Capital Medical University, Beijing, China.
Zhang M; Department of Urology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China. .; Institute of Urology, Capital Medical University, Beijing, China. .; Department of Research Ward, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, China. .
Wang X; Beijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China. .; Beijing Institute of Infectious Diseases, Beijing, 100015, China. .; National Center for Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China. .
Yan Y; Department of Urology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China. .
Pokaż więcej
Źródło:
Stem cell research & therapy [Stem Cell Res Ther] 2023 Feb 01; Vol. 14 (1), pp. 15. Date of Electronic Publication: 2023 Feb 01.
Typ publikacji:
Meta-Analysis; Journal Article
MeSH Terms:
Urinary Bladder Neoplasms*/genetics
Urinary Bladder Neoplasms*/therapy
Carcinoma, Transitional Cell*/genetics
Carcinoma, Transitional Cell*/therapy
Humans ; Urinary Bladder ; Neoplastic Stem Cells ; Immunotherapy ; Tumor Microenvironment/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Salvage Percutaneous Cryoablation for Bleeding Upper Tract Urothelial Carcinoma.
Autorzy:
de Kerviler E; Department of Radiology, Saint-Louis Hospital, APHP, Université Paris Cité, 1 Avenue Claude-Vellefaux, 75010, Paris, France. .
de Margerie-Mellon C; Department of Radiology, Saint-Louis Hospital, APHP, Université Paris Cité, 1 Avenue Claude-Vellefaux, 75010, Paris, France.
Dumont C; Department of Medical Oncology, Saint-Louis Hospital, APHP, Université Paris Cité, 1 Avenue Claude-Vellefaux, 75010, Paris, France.
Pachev A; Department of Radiology, Saint-Louis Hospital, APHP, Université Paris Cité, 1 Avenue Claude-Vellefaux, 75010, Paris, France.
Assouline J; Department of Radiology, Saint-Louis Hospital, APHP, Université Paris Cité, 1 Avenue Claude-Vellefaux, 75010, Paris, France.
Leleu F; Department of Radiology, Saint-Louis Hospital, APHP, Université Paris Cité, 1 Avenue Claude-Vellefaux, 75010, Paris, France.
Masson-Lecomte A; Department of Urology, Saint-Louis Hospital, APHP, Université Paris Cité, 1 Avenue Claude-Vellefaux, 75010, Paris, France.
Desgrandchamps F; Department of Urology, Saint-Louis Hospital, APHP, Université Paris Cité, 1 Avenue Claude-Vellefaux, 75010, Paris, France.
de Bazelaire C; Department of Radiology, Saint-Louis Hospital, APHP, Université Paris Cité, 1 Avenue Claude-Vellefaux, 75010, Paris, France.
Pokaż więcej
Źródło:
Cardiovascular and interventional radiology [Cardiovasc Intervent Radiol] 2023 Feb; Vol. 46 (2), pp. 255-258. Date of Electronic Publication: 2022 Nov 04.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Transitional Cell*/diagnostic imaging
Carcinoma, Transitional Cell*/surgery
Urinary Bladder Neoplasms*/surgery
Cryosurgery*/methods
Kidney Neoplasms*/diagnostic imaging
Kidney Neoplasms*/surgery
Kidney Neoplasms*/pathology
Humans ; Hematuria/etiology ; Hematuria/surgery ; Microcirculation ; Hemorrhage/diagnostic imaging ; Hemorrhage/etiology ; Hemorrhage/surgery
Czasopismo naukowe
Szczegóły
Tytuł:
Site-Specific Differences in PD-1 Blockade Success and Biomarkers in Urothelial Carcinoma Treated with Pembrolizumab.
Autorzy:
Umeda K; Department of Urology, Keio University School of Medicine, Tokyo, Japan.
Tanaka N; Department of Urology, Keio University School of Medicine, Tokyo, Japan. Electronic address: .
Yasumizu Y; Department of Urology, Keio University School of Medicine, Tokyo, Japan.
Takeda T; Department of Urology, Keio University School of Medicine, Tokyo, Japan.
Matsumoto K; Department of Urology, Keio University School of Medicine, Tokyo, Japan.
Morita S; Department of Urology, Keio University School of Medicine, Tokyo, Japan.
Kosaka T; Department of Urology, Keio University School of Medicine, Tokyo, Japan.
Mizuno R; Department of Urology, Keio University School of Medicine, Tokyo, Japan.
Oya M; Department of Urology, Keio University School of Medicine, Tokyo, Japan.
Pokaż więcej
Źródło:
Clinical genitourinary cancer [Clin Genitourin Cancer] 2023 Feb; Vol. 21 (1), pp. 128-135. Date of Electronic Publication: 2022 Aug 07.
Typ publikacji:
Journal Article
MeSH Terms:
Urinary Bladder Neoplasms*/pathology
Carcinoma, Transitional Cell*/drug therapy
Carcinoma, Transitional Cell*/pathology
Humans ; Programmed Cell Death 1 Receptor ; Prognosis ; Biomarkers ; Lymphocytes/pathology ; Neutrophils/pathology ; Retrospective Studies ; Tumor Microenvironment
Czasopismo naukowe
Szczegóły
Tytuł:
Development of resistance to FGFR inhibition in urothelial carcinoma via multiple pathways in vitro.
Autorzy:
Pettitt GA; Division of Molecular Medicine, Leeds Institute of Medical Research at St James's, St James's University Hospital, Leeds, UK.
Hurst CD; Division of Molecular Medicine, Leeds Institute of Medical Research at St James's, St James's University Hospital, Leeds, UK.
Khan Z; Division of Molecular Medicine, Leeds Institute of Medical Research at St James's, St James's University Hospital, Leeds, UK.
McPherson HR; Division of Molecular Medicine, Leeds Institute of Medical Research at St James's, St James's University Hospital, Leeds, UK.
Dunning MC; Division of Molecular Medicine, Leeds Institute of Medical Research at St James's, St James's University Hospital, Leeds, UK.
Alder O; Division of Molecular Medicine, Leeds Institute of Medical Research at St James's, St James's University Hospital, Leeds, UK.
Platt FM; Division of Molecular Medicine, Leeds Institute of Medical Research at St James's, St James's University Hospital, Leeds, UK.
Black EV; Division of Molecular Medicine, Leeds Institute of Medical Research at St James's, St James's University Hospital, Leeds, UK.
Burns JE; Division of Molecular Medicine, Leeds Institute of Medical Research at St James's, St James's University Hospital, Leeds, UK.
Knowles MA; Division of Molecular Medicine, Leeds Institute of Medical Research at St James's, St James's University Hospital, Leeds, UK.
Pokaż więcej
Źródło:
The Journal of pathology [J Pathol] 2023 Feb; Vol. 259 (2), pp. 220-232. Date of Electronic Publication: 2022 Dec 13.
Typ publikacji:
Journal Article
MeSH Terms:
Urinary Bladder Neoplasms*/drug therapy
Urinary Bladder Neoplasms*/genetics
Urinary Bladder Neoplasms*/pathology
Carcinoma, Transitional Cell*/drug therapy
Carcinoma, Transitional Cell*/genetics
Carcinoma, Transitional Cell*/pathology
Humans ; Neoplasm Recurrence, Local ; Receptors, Fibroblast Growth Factor/genetics ; Signal Transduction ; Cell Line, Tumor
Czasopismo naukowe
Szczegóły
Tytuł:
Can Oncogenic Driver Alterations be Responsible for the Lack of Immunotherapy Efficacy in First-line Advanced Urothelial Carcinoma?
Autorzy:
Kartolo A; Division of Medical Oncology, Department of Oncology, Queen's University, Kingston, ON, Canada.
Robinson A; Division of Medical Oncology, Department of Oncology, Queen's University, Kingston, ON, Canada.
Vera Badillo FE; Division of Medical Oncology, Department of Oncology, Queen's University, Kingston, ON, Canada. Electronic address: .
Pokaż więcej
Źródło:
European urology [Eur Urol] 2023 Jan; Vol. 83 (1), pp. 1-2. Date of Electronic Publication: 2022 May 20.
Typ publikacji:
Editorial
MeSH Terms:
Carcinoma, Transitional Cell*/drug therapy
Carcinoma, Transitional Cell*/pathology
Urinary Bladder Neoplasms*/drug therapy
Urinary Bladder Neoplasms*/pathology
Humans ; Immunotherapy
Opinia redakcyjna
Szczegóły
Tytuł:
Both radiographical and pathological lymph node statuses are independent predictors for survival following neoadjuvant chemotherapy and radical cystectomy for cT3/4 or cN+ bladder cancer.
Autorzy:
Wagner J; Department of Urology, School of Medicine, Klinikum Rechts der Isar, Technical University of Munich, Ismaningerstraße 22, 81675, Munich, Germany.
Simon R; Department of Urology, School of Medicine, Klinikum Rechts der Isar, Technical University of Munich, Ismaningerstraße 22, 81675, Munich, Germany.
Büchler JW; Department of Urology, School of Medicine, Klinikum Rechts der Isar, Technical University of Munich, Ismaningerstraße 22, 81675, Munich, Germany.
Kirchhoff F; Department of Urology, School of Medicine, Klinikum Rechts der Isar, Technical University of Munich, Ismaningerstraße 22, 81675, Munich, Germany.
Kehl V; Institute for AI and Informatics in Medicine, Technical University of Munich, Munich, Germany.
Retz M; Department of Urology, School of Medicine, Klinikum Rechts der Isar, Technical University of Munich, Ismaningerstraße 22, 81675, Munich, Germany.
Gschwend JE; Department of Urology, School of Medicine, Klinikum Rechts der Isar, Technical University of Munich, Ismaningerstraße 22, 81675, Munich, Germany.
Sauter A; Institute for Diagnostic and Interventional Radiology, Technical University of Munich, Munich, Germany.
Horn T; Department of Urology, School of Medicine, Klinikum Rechts der Isar, Technical University of Munich, Ismaningerstraße 22, 81675, Munich, Germany. .
Pokaż więcej
Źródło:
World journal of urology [World J Urol] 2023 Jan; Vol. 41 (1), pp. 101-107. Date of Electronic Publication: 2022 Oct 21.
Typ publikacji:
Journal Article
MeSH Terms:
Urinary Bladder Neoplasms*/diagnostic imaging
Urinary Bladder Neoplasms*/drug therapy
Carcinoma, Transitional Cell*/diagnostic imaging
Carcinoma, Transitional Cell*/surgery
Humans ; Cystectomy/methods ; Neoadjuvant Therapy ; Treatment Outcome ; Lymphatic Metastasis/pathology ; Lymph Nodes/pathology ; Lymph Node Excision ; Neoplasm Staging
Czasopismo naukowe
Szczegóły
Tytuł:
Upper tract urothelial carcinoma in Germany: epidemiological data and surgical treatment trends in a total population analysis from 2006 to 2019.
Autorzy:
Herout R; Department of Urology, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany. .
Baunacke M; Department of Urology, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.
Flegar L; Department of Urology, Philipps-University Marburg, Marburg, Germany.
Borkowetz A; Department of Urology, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.
Reicherz A; Department of Urology, Ruhr-University of Bochum, Marien Hospital Herne, Herne, Germany.
Koch R; Department of Urology, Philipps-University Marburg, Marburg, Germany.
Kraywinkel K; National Center for Cancer Registry Data, Robert Koch Institute, Berlin, Germany.
Thomas C; Department of Urology, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.
Groeben C; Department of Urology, Philipps-University Marburg, Marburg, Germany.
Huber J; Department of Urology, Philipps-University Marburg, Marburg, Germany.
Pokaż więcej
Źródło:
World journal of urology [World J Urol] 2023 Jan; Vol. 41 (1), pp. 127-133. Date of Electronic Publication: 2022 Nov 29.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Transitional Cell*/epidemiology
Carcinoma, Transitional Cell*/surgery
Carcinoma, Transitional Cell*/pathology
Urinary Bladder Neoplasms*/surgery
Ureteral Neoplasms*/epidemiology
Ureteral Neoplasms*/surgery
Ureteral Neoplasms*/pathology
Ureter*/surgery
Ureter*/pathology
Kidney Neoplasms*/epidemiology
Kidney Neoplasms*/surgery
Kidney Neoplasms*/pathology
Humans ; Germany/epidemiology ; Retrospective Studies ; Nephrectomy/methods
Czasopismo naukowe
Szczegóły
Tytuł:
Challenges and opportunities in the management of non-urothelial bladder cancers.
Autorzy:
Brown JT; Winship Cancer Institute, Emory University, Atlanta, GA, United States; Emory University School of Medicine, Department of Hematology and Medical Oncology, Atlanta, GA, United States. Electronic address: .
Narayan VM; Winship Cancer Institute, Emory University, Atlanta, GA, United States; Emory University School of Medicine, Department of Urology, Atlanta, GA, United States.
Joshi SS; Winship Cancer Institute, Emory University, Atlanta, GA, United States; Emory University School of Medicine, Department of Urology, Atlanta, GA, United States.
Harik L; Winship Cancer Institute, Emory University, Atlanta, GA, United States; Emory University School of Medicine, Department of Pathology and Laboratory Medicine, Atlanta, GA, United States.
Jani AB; Winship Cancer Institute, Emory University, Atlanta, GA, United States; Emory University School of Medicine, Department of Radiation Oncology, Atlanta, GA, United States.
Bilen MA; Winship Cancer Institute, Emory University, Atlanta, GA, United States; Emory University School of Medicine, Department of Hematology and Medical Oncology, Atlanta, GA, United States.
Pokaż więcej
Źródło:
Cancer treatment and research communications [Cancer Treat Res Commun] 2023; Vol. 34, pp. 100663. Date of Electronic Publication: 2022 Dec 05.
Typ publikacji:
Review; Journal Article
MeSH Terms:
Urinary Bladder Neoplasms*/therapy
Urinary Bladder Neoplasms*/drug therapy
Carcinoma, Transitional Cell*/therapy
Carcinoma, Transitional Cell*/drug therapy
Carcinoma, Small Cell*
Carcinoma, Squamous Cell*/pathology
Adenocarcinoma*/therapy
Humans ; Prospective Studies
Czasopismo naukowe
Szczegóły
Tytuł:
Bladder Preservation for Muscle-Invasive Bladder Cancer With Variant Histology.
Autorzy:
Brocklehurst A; North-West Deanery, United Kingdom. Electronic address: .
Varughese M; Royal Devon & Exeter NHS Foundation Trust, University of Exeter, United Kingdom.
Birtle A; Rosemere Cancer Centre, Preston, Lancs; University of Manchester; University of Central Lancashire.
Pokaż więcej
Źródło:
Seminars in radiation oncology [Semin Radiat Oncol] 2023 Jan; Vol. 33 (1), pp. 62-69.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Urinary Bladder Neoplasms*
Carcinoma, Transitional Cell*/therapy
Carcinoma, Transitional Cell*/pathology
Humans ; Urinary Bladder/pathology ; Retrospective Studies ; Quality of Life ; Muscles/pathology ; Treatment Outcome
Czasopismo naukowe
Szczegóły
Tytuł:
Urothelial carcinoma in a Russian tortoise (Testudohorsfieldii).
Autorzy:
Hetterich J; Department of Small Mammal, Reptile and Avian Diseases, University of Veterinary Medicine Hannover, Foundation, Hannover, Germany. Electronic address: .
Schmidt V; Clinic for Birds and Reptiles, Faculty of Veterinary Medicine, University of Leipzig, Leipzig, Germany.
Herth M; Department of Small Mammal, Reptile and Avian Diseases, University of Veterinary Medicine Hannover, Foundation, Hannover, Germany.
Merhof K; Department of Small Animal Diseases, University of Veterinary Medicine Hannover, Foundation, Hannover, Germany.
Pees M; Department of Small Mammal, Reptile and Avian Diseases, University of Veterinary Medicine Hannover, Foundation, Hannover, Germany.
Pokaż więcej
Źródło:
Journal of comparative pathology [J Comp Pathol] 2023 Jan; Vol. 200, pp. 18-22. Date of Electronic Publication: 2023 Jan 05.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Transitional Cell*/pathology
Carcinoma, Transitional Cell*/veterinary
Urinary Bladder Neoplasms*/veterinary
Turtles*
Kidney Neoplasms*/veterinary
Kidney Neoplasms*/pathology
Female ; Animals ; Kidney/pathology ; Russia ; Kidney Pelvis/pathology
Czasopismo naukowe
Szczegóły
Tytuł:
The evolving role of checkpoint inhibitors in the treatment of urothelial carcinoma.
Autorzy:
Tang G; Department of Urology, Xiangya Hospital of Central South University, Changsha, China.
Liu J; Department of Oncology, Xiangya Hospital of Central South University, Changsha, China.
Qi L; Department of Urology, Xiangya Hospital of Central South University, Changsha, China.
Li Y; Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, China.
Pokaż więcej
Źródło:
British journal of clinical pharmacology [Br J Clin Pharmacol] 2023 Jan; Vol. 89 (1), pp. 93-113. Date of Electronic Publication: 2022 Sep 09.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Urinary Bladder Neoplasms*/drug therapy
Urinary Bladder Neoplasms*/pathology
Carcinoma, Transitional Cell*/drug therapy
Carcinoma, Transitional Cell*/pathology
Humans ; B7-H1 Antigen/therapeutic use ; Immune Checkpoint Proteins/therapeutic use ; Antibodies, Monoclonal/therapeutic use ; Immunotherapy
Czasopismo naukowe
Szczegóły
Tytuł:
Five-gene signature for the prediction of response to immune checkpoint inhibitors in patients with gastric and urothelial carcinomas.
Autorzy:
Kang SY; Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Heo YJ; The Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Kwon GY; Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Lee J; Department of Medicine, Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Park SH; Department of Medicine, Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Kim KM; Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Center of Companion Diagnostics, Samsung Medical Center, Seoul, Republic of Korea. Electronic address: .
Pokaż więcej
Źródło:
Pathology, research and practice [Pathol Res Pract] 2023 Jan; Vol. 241, pp. 154233. Date of Electronic Publication: 2022 Nov 17.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Transitional Cell*/drug therapy
Carcinoma, Transitional Cell*/genetics
Urinary Bladder Neoplasms*/drug therapy
Urinary Bladder Neoplasms*/genetics
Humans ; Immune Checkpoint Inhibitors/therapeutic use ; B7-H1 Antigen ; RNA, Messenger
Czasopismo naukowe
Szczegóły
Tytuł:
Investigating PSMA differential expression in canine uroepithelial carcinomas to aid disease-based stratification and guide therapeutic selection.
Autorzy:
Berry MR; Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, IL, 61802, USA.; Department of Pathobiology, College of Veterinary Medicine, University of Illinois, Urbana, IL, 61802, USA.
Fadl-Alla BA; Department of Pathobiology, College of Veterinary Medicine, University of Illinois, Urbana, IL, 61802, USA.
Samuelson J; Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, IL, 61802, USA.
Rosol TJ; Heritage College of Osteopathic Medicine, Ohio University, Athens, OH, 45701, USA.
Fan TM; Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, IL, 61802, USA. .; Department of Pathobiology, College of Veterinary Medicine, University of Illinois, Urbana, IL, 61802, USA. .; Cancer Center at Illinois, University of Illinois, Urbana, IL, 61802, USA. .
Pokaż więcej
Źródło:
BMC veterinary research [BMC Vet Res] 2022 Dec 20; Vol. 18 (1), pp. 441. Date of Electronic Publication: 2022 Dec 20.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Transitional Cell*/metabolism
Carcinoma, Transitional Cell*/veterinary
Urinary Bladder Neoplasms*/metabolism
Urinary Bladder Neoplasms*/veterinary
Prostatic Neoplasms*/metabolism
Prostatic Neoplasms*/veterinary
Dog Diseases*/diagnosis
Dog Diseases*/drug therapy
Dog Diseases*/genetics
Humans ; Male ; Dogs ; Animals ; Vinblastine/therapeutic use ; Antigens, Surface ; Prostate/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Cohort profile: Bladder Cancer Data Base Sweden (BladderBaSe) 2.0.
Autorzy:
Häggström C; Department of Surgical Sciences, Uppsala University, Uppsala, Sweden .; Northern Registry Centre, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
Hagberg O; Department of Translational Medicine, Lund University, Lund, Sweden.
Gårdmark T; Department of Clinical Sciences, Karolinska Institute, Danderyd Hospital, Stockholm, Sweden.
Aljabery F; Department of Clinical and Experimental Medicine, Division of Urology, Linköping University, Linköping, Sweden.
Ströck V; Department of Urology, Sahlgrenska University Hospital, Gothenburg, Sweden.; Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden.
Hosseini A; Department of Urology, Karolinska University Hospital, Stockholm, Sweden.
Sherif A; Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden.
Malmstrom PU; Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Söderkvist K; Department of Radiation Sciences, Umeå University, Umeå, Sweden.
Ullén A; Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.; Department of Pelvic Cancer, Genitourinary Oncology and Urology unit, Karolinska University Hospital, Stockholm, Sweden.
Jerlström T; School of Medical Sciences, Örebro University, Örebro, Sweden.
Jahnson S; Department of Clinical and Experimental Medicine, Division of Urology, Linköping University, Linköping, Sweden.
Liedberg F; Department of Translational Medicine, Lund University, Lund, Sweden.; Department of Urology, Skåne University Hospital, Malmö, Sweden.
Holmberg L; Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.; Translational Oncology & Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
Pokaż więcej
Źródło:
BMJ open [BMJ Open] 2022 Dec 20; Vol. 12 (12), pp. e064898. Date of Electronic Publication: 2022 Dec 20.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Urinary Bladder Neoplasms*/therapy
Urinary Bladder Neoplasms*/drug therapy
Carcinoma, Transitional Cell*/epidemiology
Carcinoma, Transitional Cell*/therapy
Male ; Humans ; Female ; Sweden/epidemiology ; Prognosis ; Treatment Outcome ; Cystectomy ; Retrospective Studies
Czasopismo naukowe
Szczegóły
Tytuł:
Adjuvant Radiotherapy for Upper Tract Urothelial Carcinoma: Systematic Review and Meta-Analysis.
Autorzy:
Zalay O; Division of Radiation Oncology, University of Ottawa, Ottawa, ON K1H 8L6, Canada.
Yan M; Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, ON M5G 2C1, Canada.
Sigurdson S; Department of Oncology, McMaster University, Hamilton, ON L8V 5C2, Canada.
Malone S; Division of Radiation Oncology, University of Ottawa, Ottawa, ON K1H 8L6, Canada.
Vera-Badillo FE; Department of Oncology, Queen's University, Kingston, ON K7L 5P9, Canada.; Canadian Cancer Trials Group, Queen's Cancer Research Institute, Kingston, ON K7L 2V5, Canada.
Mahmud A; Department of Oncology, Queen's University, Kingston, ON K7L 5P9, Canada.
Pokaż więcej
Źródło:
Current oncology (Toronto, Ont.) [Curr Oncol] 2022 Dec 20; Vol. 30 (1), pp. 19-36. Date of Electronic Publication: 2022 Dec 20.
Typ publikacji:
Meta-Analysis; Systematic Review; Journal Article; Review
MeSH Terms:
Carcinoma, Transitional Cell*/radiotherapy
Carcinoma, Transitional Cell*/surgery
Carcinoma, Transitional Cell*/drug therapy
Urinary Bladder Neoplasms*
Humans ; Radiotherapy, Adjuvant ; Retrospective Studies ; Prospective Studies ; Neoplasm Recurrence, Local
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Derivation and external validation of dendritic cell-related gene signatures for predicting prognosis and immunotherapy efficacy in bladder urothelial carcinoma.
Autorzy:
An B; Department of Urology, Qilu Hospital of Shandong University, Jinan, China.
Guo Z; Department of Urology, Qilu Hospital of Shandong University, Jinan, China.
Wang J; Department of Urology, Qilu Hospital of Shandong University, Jinan, China.
Zhang C; Department of Urology, Qilu Hospital of Shandong University, Jinan, China.
Zhang G; Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI, United States.
Yan L; Department of Urology, Qilu Hospital of Shandong University, Jinan, China.
Pokaż więcej
Źródło:
Frontiers in immunology [Front Immunol] 2022 Dec 12; Vol. 13, pp. 1080947. Date of Electronic Publication: 2022 Dec 12 (Print Publication: 2022).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Transitional Cell*/genetics
Carcinoma, Transitional Cell*/therapy
Urinary Bladder Neoplasms*/genetics
Urinary Bladder Neoplasms*/therapy
Humans ; Ryanodine Receptor Calcium Release Channel ; Urinary Bladder ; Prognosis ; Immunotherapy ; Dendritic Cells
Czasopismo naukowe
Szczegóły
Tytuł:
Circulating extracellular vesicles carrying Firmicutes reflective of the local immune status may predict clinical response to pembrolizumab in urothelial carcinoma patients.
Autorzy:
Jingushi K; Laboratory of Molecular and Cellular Physiology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan.
Kawashima A; Department of Urology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan. .
Saito T; Department of Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.; Department of Clinical Research in Tumor Immunology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Kanazawa T; Department of Clinical Research in Tumor Immunology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.; Drug Discovery & Disease Research Laboratory, Shionogi & Co. Ltd, Toyonaka, Osaka, Japan.
Motooka D; Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
Kimura T; Reverse Translational Project, Center for Rare Disease Research, National Institute of Biomedical Innovation, Health and Nutrition (NIBIOHN), Minoh, Osaka, Japan.
Mita M; KAGAMI Inc., Ibaraki, Osaka, Japan.
Yamamoto A; Department of Urology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Uemura T; Department of Urology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Yamamichi G; Department of Urology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Okada K; Department of Urology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Tomiyama E; Department of Urology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Koh Y; Department of Urology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Matsushita M; Department of Urology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Kato T; Department of Urology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Hatano K; Department of Urology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Uemura M; Department of Urology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Tsujikawa K; Laboratory of Molecular and Cellular Physiology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan.
Wada H; Department of Clinical Research in Tumor Immunology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Nonomura N; Department of Urology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Pokaż więcej
Źródło:
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2022 Dec; Vol. 71 (12), pp. 2999-3011. Date of Electronic Publication: 2022 May 22.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Transitional Cell*/drug therapy
Carcinoma, Transitional Cell*/metabolism
Urinary Bladder Neoplasms*/drug therapy
Urinary Bladder Neoplasms*/metabolism
Extracellular Vesicles*
Humans ; Firmicutes ; DNA, Bacterial ; RNA, Ribosomal, 16S/genetics
Czasopismo naukowe
Szczegóły
Tytuł:
Impact of germline HLA genotypes on clinical outcomes in patients with urothelial cancer treated with pembrolizumab.
Autorzy:
Takahashi S; Department of Urology, Akita University School of Medicine, Akita, Japan.
Narita S; Department of Urology, Akita University School of Medicine, Akita, Japan.
Fujiyama N; Clinical Research Support Center, Akita University Hospital, Akita, Japan.
Hatakeyama S; Department of Urology, Hirosaki University School of Medicine, Hirosaki, Japan.
Kobayashi T; Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Kato R; Department of Urology, Iwate Medical School of Medicine, Iwate, Japan.
Naito S; Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan.
Sakatani T; Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Kashima S; Department of Urology, Akita University School of Medicine, Akita, Japan.
Koizumi A; Department of Urology, Akita University School of Medicine, Akita, Japan.
Yamamoto R; Department of Urology, Akita University School of Medicine, Akita, Japan.
Nara T; Department of Urology, Akita University School of Medicine, Akita, Japan.
Kanda S; Department of Urology, Akita University School of Medicine, Akita, Japan.
Numakura K; Department of Urology, Akita University School of Medicine, Akita, Japan.
Saito M; Department of Urology, Akita University School of Medicine, Akita, Japan.
Obara W; Department of Urology, Iwate Medical School of Medicine, Iwate, Japan.
Tsuchiya N; Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan.
Ohyama C; Department of Urology, Hirosaki University School of Medicine, Hirosaki, Japan.
Ogawa O; Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Habuchi T; Department of Urology, Akita University School of Medicine, Akita, Japan.
Pokaż więcej
Źródło:
Cancer science [Cancer Sci] 2022 Dec; Vol. 113 (12), pp. 4059-4069. Date of Electronic Publication: 2022 Sep 24.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Transitional Cell*/genetics
Carcinoma, Transitional Cell*/pathology
Urinary Bladder Neoplasms*/genetics
Urinary Bladder Neoplasms*/pathology
Genes, MHC Class II*
Genes, MHC Class I*
Humans ; Alleles ; Genotype ; Progression-Free Survival
Czasopismo naukowe
Szczegóły
Tytuł:
GATA3 expression loss is linked to stage progression but is unrelated to prognosis in muscle-invasive urothelial carcinoma of the bladder.
Autorzy:
Plage H; Department of Urology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, 10117 Berlin, Germany.
Samtleben H; Department of Pathology, Academic Hospital Fuerth, 90766 Fuerth, Germany.
Hofbauer S; Department of Urology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, 10117 Berlin, Germany.
Kornienko K; Department of Urology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, 10117 Berlin, Germany.
Weinberger S; Department of Urology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, 10117 Berlin, Germany.
Bruch PG; Department of Urology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, 10117 Berlin, Germany.
Elezkurtaj S; Institute of Pathology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, 10117 Berlin, Germany.
Roßner F; Institute of Pathology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, 10117 Berlin, Germany.
Schallenberg S; Institute of Pathology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, 10117 Berlin, Germany.
Kluth M; Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Lennartz M; Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Blessin NC; Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Marx AH; Department of Pathology, Academic Hospital Fuerth, 90766 Fuerth, Germany.
Fisch M; Department of Urology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Rink M; Department of Urology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Slojewski M; Department of Urology and Urological Oncology, Pomeranian Medical University, 70-204 Szczeci, Poland.
Kaczmarek K; Department of Urology and Urological Oncology, Pomeranian Medical University, 70-204 Szczeci, Poland.
Ecke T; Department of Urology, Helios Hospital Bad Saarow, 15526 Bad Saarow, Germany.
Hallmann S; Department of Urology, Helios Hospital Bad Saarow, 15526 Bad Saarow, Germany.
Koch S; Department of Pathology, Helios Hospital Bad Saarow, 15526 Bad Saarow, Germany.
Adamini N; Department of Urology, Albertinen Hospital, 22457 Hamburg, Germany.
Minner S; Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Simon R; Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany. Electronic address: .
Sauter G; Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Klatte T; Department of Urology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, 10117 Berlin, Germany.
Schlomm T; Department of Urology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, 10117 Berlin, Germany.
Horst D; Institute of Pathology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, 10117 Berlin, Germany.
Zecha H; Department of Urology, Albertinen Hospital, 22457 Hamburg, Germany.
Pokaż więcej
Źródło:
Human pathology [Hum Pathol] 2022 Dec; Vol. 130, pp. 10-17. Date of Electronic Publication: 2022 Sep 21.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Transitional Cell*/genetics
Carcinoma, Transitional Cell*/pathology
GATA3 Transcription Factor*/genetics
GATA3 Transcription Factor*/metabolism
Urinary Bladder Neoplasms*/genetics
Urinary Bladder Neoplasms*/metabolism
Humans ; Biomarkers, Tumor/metabolism ; Immunohistochemistry ; Muscles/metabolism ; Muscles/pathology ; Prognosis ; Urinary Bladder/pathology ; Urothelium/pathology
Czasopismo naukowe
Szczegóły
Tytuł:
Routine urethroscopic surveillance is of limited value after radical cystectomy: a single centre retrospective cohort analysis.
Autorzy:
Devlin CM; Department of Urology, Bradford Teaching Hospitals NHS Foundation Trust, Duckworth Lane, Bradford, BD9 6RJ, UK.
Molokwu CN; Department of Urology, Bradford Teaching Hospitals NHS Foundation Trust, Duckworth Lane, Bradford, BD9 6RJ, UK. .
Wood B; Department of Urology, Bradford Teaching Hospitals NHS Foundation Trust, Duckworth Lane, Bradford, BD9 6RJ, UK.
Yuen KK; Department of Urology, Bradford Teaching Hospitals NHS Foundation Trust, Duckworth Lane, Bradford, BD9 6RJ, UK.
Singh R; Department of Urology, Bradford Teaching Hospitals NHS Foundation Trust, Duckworth Lane, Bradford, BD9 6RJ, UK.
Chahal R; Department of Urology, Bradford Teaching Hospitals NHS Foundation Trust, Duckworth Lane, Bradford, BD9 6RJ, UK.
Pokaż więcej
Źródło:
International urology and nephrology [Int Urol Nephrol] 2022 Dec; Vol. 54 (12), pp. 3139-3144. Date of Electronic Publication: 2022 Aug 11.
Typ publikacji:
Journal Article
MeSH Terms:
Urinary Bladder Neoplasms*/surgery
Urinary Bladder Neoplasms*/pathology
Carcinoma, Transitional Cell*/surgery
Carcinoma, Transitional Cell*/pathology
Urethral Neoplasms*/diagnosis
Urethral Neoplasms*/surgery
Urethral Neoplasms*/pathology
Female ; Humans ; Cystectomy ; Retrospective Studies ; Urinary Bladder/surgery ; Urinary Bladder/pathology ; Neoplasm Recurrence, Local/pathology ; Cohort Studies
Czasopismo naukowe
Szczegóły
Wyświetlanie 1-20 z 7106

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies

Prześlij opinię

Twoje opinie są dla nas bardzo ważne i mogą być niezwykle pomocne w pokazaniu nam, gdzie możemy dokonać ulepszeń. Bylibyśmy bardzo wdzięczni za poświęcenie kilku chwil na wypełnienie krótkiego formularza.

Formularz